1. Home
  2. NAMS vs MGNI Comparison

NAMS vs MGNI Comparison

Compare NAMS & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • MGNI
  • Stock Information
  • Founded
  • NAMS 2019
  • MGNI 2007
  • Country
  • NAMS Netherlands
  • MGNI United States
  • Employees
  • NAMS N/A
  • MGNI N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • MGNI Computer Software: Programming Data Processing
  • Sector
  • NAMS Health Care
  • MGNI Technology
  • Exchange
  • NAMS Nasdaq
  • MGNI Nasdaq
  • Market Cap
  • NAMS 3.1B
  • MGNI 3.1B
  • IPO Year
  • NAMS N/A
  • MGNI N/A
  • Fundamental
  • Price
  • NAMS $36.14
  • MGNI $19.88
  • Analyst Decision
  • NAMS Strong Buy
  • MGNI Strong Buy
  • Analyst Count
  • NAMS 10
  • MGNI 11
  • Target Price
  • NAMS $43.70
  • MGNI $26.18
  • AVG Volume (30 Days)
  • NAMS 1.4M
  • MGNI 2.6M
  • Earning Date
  • NAMS 11-06-2025
  • MGNI 11-05-2025
  • Dividend Yield
  • NAMS N/A
  • MGNI N/A
  • EPS Growth
  • NAMS N/A
  • MGNI N/A
  • EPS
  • NAMS N/A
  • MGNI 0.29
  • Revenue
  • NAMS $64,006,000.00
  • MGNI $685,074,000.00
  • Revenue This Year
  • NAMS N/A
  • MGNI $2.09
  • Revenue Next Year
  • NAMS $1.67
  • MGNI $11.41
  • P/E Ratio
  • NAMS N/A
  • MGNI $70.47
  • Revenue Growth
  • NAMS 762.15
  • MGNI 5.52
  • 52 Week Low
  • NAMS $14.06
  • MGNI $8.22
  • 52 Week High
  • NAMS $41.47
  • MGNI $26.65
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 60.09
  • MGNI 48.64
  • Support Level
  • NAMS $34.34
  • MGNI $18.45
  • Resistance Level
  • NAMS $37.21
  • MGNI $20.35
  • Average True Range (ATR)
  • NAMS 2.47
  • MGNI 0.81
  • MACD
  • NAMS -0.34
  • MGNI 0.34
  • Stochastic Oscillator
  • NAMS 46.32
  • MGNI 86.98

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About MGNI Magnite Inc.

Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.

Share on Social Networks: